Literature DB >> 10429961

High prevalence of pulmonary diffusion abnormalities without interstitial changes in long-term survivors of liver transplantation.

R Ewert1, S Mutze, G Schachschal, H Lochs, M Plauth.   

Abstract

Abnormalities in lung function are frequent findings in patients with terminal stage chronic liver disease. While spirometric parameters improve early after liver transplantation, a reduction in diffusion capacity has been reported up to 15 months after transplantation. It is unknown to what extent this disturbance in gas exchange occurs among long term survivors after liver transplantation. We assessed lung function in terms of spirometry, and gas exchange as well as pulmonary morphology by high resolution computed tomography (HRCT) in 40 patients 38 months (median, range 20-147 months) after liver transplantation. The prevalence of restrictive or obstructive changes was not different from predicted values. For the whole group of long-term survivors the carbon monoxide transfer coefficient (KCO) was reduced to 71.3 + 12.0% predicted (P < 0.05). HRCT revealed interstitial changes in only 2/40 (5.0%), emphysematous bullae in 2/40 (5.0%) and pleural thickening in 9/40 (22.5%). Diffusion abnormalities are prevalent in the majority of patients after liver transplantation, whereas spirometric abnormalities are absent also in the long term. The high prevalence of impaired gas exchange and the absence of interstitial lesions imply that changes in pulmonary blood vessels are the most likely cause.

Entities:  

Mesh:

Year:  1999        PMID: 10429961     DOI: 10.1007/s001470050214

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

Review 1.  Cirrhosis and hepatopulmonary syndrome.

Authors:  Gokhan Tumgor
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

2.  CT Scan Does Not Differentiate Patients with Hepatopulmonary Syndrome from Other Patients with Liver Disease.

Authors:  Yingming Amy Chen; Vikramaditya Prabhudesai; Helene Castel; Samir Gupta
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.